OncoCyte Corporation (0KCC.L)
| Previous close | 3.0300 |
| Open | 3.1950 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 3.1950 - 3.1950 |
| 52-week range | 0.2082 - 4.2256 |
| Volume | |
| Avg. volume | 382 |
| Market cap | 290.931M |
| Beta (5Y monthly) | 0.98 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.7710 |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireMedTech Gurus Podcast Features Oncocyte CEO Josh Riggs in "Take Advantage of the Moment" Episode
HOLLAND, Mich., July 11, 2024 (GLOBE NEWSWIRE) -- MedTech Gurus, a leading podcast focused on the forefront of medical technology, featured Oncocyte Corporation (NASDAQ: OCX) CEO Josh Riggs in its latest episode, "Take Advantage of the Moment." In this episode, Riggs highlights Oncocyte's innovative strategies in molecular diagnostic technology and the significant impact of this technology on patient care. Hosted by Tom Hickey, a partner at Excelerant Consulting and a seasoned expert in medical
GlobeNewswireOncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leader within the financial markets and news community, announces the release of an article highlighting the precision diagnostics company, Oncocyte’s (Nasdaq: OCX) appointment of leading finance executive, Andrea James, as Chief Financial Officer. This strategic move comes at a pivotal time as Oncocyte prepares for significant commercial and regulatory milestones expected in 2024 and 2025. Under the leadership of CEO Josh Riggs, On
GlobeNewswireOncocyte Appoints Andrea James as Chief Financial Officer
IRVINE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that it has appointed leading finance executive, Andrea James, to the position of Chief Financial Officer. “We are thrilled to welcome Andrea as we approach the inflection point of commercial launch,” Oncocyte CEO Josh Riggs said. “She has a proven track record of guiding financial strategy through multiple phases of growth, raising and stewarding capital, and bu
